Total protein is an effective loading control for cerebrospinal fluid western blots

Journal of Neuroscience Methods

Volumn 251, Issue , 2015, Pages 72-82

  Collins, Mahlon A ^a,b   An, Jiyan ^b   Peller, Danielle ^b   Bowser, Robert ^b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b BARROW NEUROLOGICAL INSTITUTE   (United States)

Author keywords

Cerebrospinal fluid; Loading control; Total protein stain; Western blot

Indexed keywords

CEREBROSPINAL FLUID TOTAL PROTEIN; COMPLEMENT COMPONENT C3; CYSTATIN C; GREEN FLUORESCENT PROTEIN; IODINE; PROTEIN; UNCLASSIFIED DRUG; ALBUMINOID; COLORING AGENT; PROTEIN CEREBROSPINAL FLUID LEVEL;

AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; CEREBROSPINAL FLUID; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; INTERMETHOD COMPARISON; PRIORITY JOURNAL; STAINING; WESTERN BLOTTING; ANALYSIS; FEMALE; LUMBAR PUNCTURE; MALE; METABOLISM; PROCEDURES; PROTEIN CEREBROSPINAL FLUID LEVEL; STATISTICAL MODEL; STUDENT; UNIVERSITY;

ALBUMINS; BLOTTING, WESTERN; CEREBROSPINAL FLUID PROTEINS; COLORING AGENTS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GREEN FLUORESCENT PROTEINS; HUMANS; LINEAR MODELS; MALE; SPINAL PUNCTURE; STAINING AND LABELING; STUDENTS; UNIVERSITIES;

EID: 84930614681     PISSN: 01650270     EISSN: 1872678X     Source Type: Journal    
DOI: 10.1016/j.jneumeth.2015.05.011     Document Type: Article

References (66)

1. Aldridge G.M., Podrebarac D.M., Greenough W.T., Weiler I.J. The use of total protein stains as loading controls: an alternative to high-abundance single-protein controls in semi-quantitative immunoblotting. J Neurosci Methods 2008, 172:250-254.
2. Barker P.E. Cancer biomarker validation: standards and process: roles for the National Institute of Standards and Technology (NIST). Ann N Y Acad Sci 2003, 983:142-150.
3. Castaneyra-Ruiz L., Gonzalez-Marrero I., Gonzalez-Toledo J.M., Castaneyra-Ruiz A., de Paz-Carmona H., Castañeyra-Perdomo A., et al. Aquaporin-4 expression in the cerebrospinal fluid in congenital human hydrocephalus. Fluids Barriers CNS 2013, 10:18.
4. Conly J.M., Ronald A.R. Cerebrospinal fluid as a diagnostic body fluid. Am J Med 1983, 75:102-108.
5. Cummings J., Ward T.H., Greystoke A., Ranson M., Dive C. Biomarker method validation in anticancer drug development. Br J Pharmacol 2008, 153:646-656.
6. Cushing H. Studies on the cerebro-spinal fluid: I Introduction. J Med Res 1914, 31:1-19.
7. Davidsson P., Sjogren M., Andreasen N., Lindbjer M., et al. Studies of the pathophysiological mechanisms in frontotemporal dementia by proteome analysis of CSF proteins. Brain Res Mol Brain Res 2002, 109:128-133.
8. Degasperi A., Birtwistle M.R., Volinsky N., Rauch J., Kolch W., Kholodenko B.N. Evaluating strategies to normalise biological replicates of Western blot data. PLoS One 2014, 9:e87293.
9. Ditzen C., Tang N., Jastorff A.M., Teplytska L., Yassouridis A., Maccarrone G., et al. Cerebrospinal fluid biomarkers for major depression confirm relevance of associated pathophysiology. Neuropsychopharmacology 2012, 37:1013-1025.
10. Dubitsky A., DeCollibus D., Ortolano G.A. Sensitive fluorescent detection of protein on nylon membranes. J Biochem Biophys Methods 2002, 51:47-56.
11. Eaton S.L., Roche S.L., Llavero Hurtado M., Oldknow K.J., Farquharson C., Gillingwater T.H., et al. Total protein analysis as a reliable loading control for quantitative fluorescent Western blotting. PLoS One 2013, 8:e72457.
12. Ferguson R.E., Carroll H.P., Harris A., Maher E.R., Selby P.J., Banks R.E. Housekeeping proteins: a preliminary study illustrating some limitations as useful references in protein expression studies. Proteomics 2005, 5:566-571.
13. Ferreira, T. and Rasband, W.S., ImageJ User Guide - IJ 1.46. imagej.nih.gov/ij/docs/guide/, 2010-2012.
14. Ganesalingam J., An J., Shaw C.E., Shaw G., Lacomis D., Bowser R. Combination of neurofilament heavy chain and complement C3 as CSF biomarkers for ALS. J Neurochem 2011, 117:528-537.
15. Gao J., Garulacan L.A., Storm S.M., Opiteck G.J., Dubaquie Y., Hefta S.A., et al. Biomarker discovery in biological fluids. Methods 2005, 35:291-302.
16. Gassmann M., Grenacher B., Rohde B., Vogel J. Quantifying Western blots: pitfalls of densitometry. Electrophoresis 2009, 30:1845-1855.
17. Ghasemzadeh N., Nyberg F., Hjerten S. Highly selective artificial gel antibodies for detection and quantification of biomarkers in clinical samples. II. Albumin in body fluids of patients with neurological disorders. J Sep Sci 2008, 31:3954-3958.
18. Gilda J.E., Gomes A.V. Stain-Free total protein staining is a superior loading control to beta-actin for Western blots. Anal Biochem 2013, 440:186-188.
19. Gingrich J.C., Davis D.R., Nguyen Q. Multiplex detection and quantitation of proteins on western blots using fluorescent probes. Biotechniques 2000, 29:636-642.
20. Goldknopf I.L., Sheta E.A., Bryson J., Folsom B., Wilson C., Duty J., et al. Complement C3c and related protein biomarkers in amyotrophic lateral sclerosis and Parkinson's disease. Biochem Biophys Res Commun 2006, 342:1034-1039.
21. Greer S., Honeywell R., Geletu M., Arulanandam R., Rantis L. Housekeeping genes; expression levels may change with density of cultured cells. J Immunol Methods 2010, 355:76-79.
22. Guldbrandsen A., Vethe H., Farag Y., Oveland E., Garberg H., Berle M., et al. In-depth Characterization of the Cerebrospinal Fluid (CSF) Proteome Displayed Through the CSF Proteome Resource (CSF-PR). Mol Cell Proteomics 2014, 13:3152-3163.
23. Hong Z., Shi M., Chung K.A., Quinn J.F., Peskind E.R., Galasko D., et al. Dj-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of parkinson's disease. Brain 2010, 133:713-726.
24. Hu W.T., Watts K., Grossman M., Glass J., Lah J.J., Hales C., et al. Reduced CSF p-Tau181 to Tau ratio is a biomarker for FTLD-TDP. Neurology 2013, 81:1945-1952.
25. Kalinina J., Peng J., Ritchie J.C., Van Meir E.G. Proteomics of gliomas: initial biomarker discovery and evolution of technology. Neuro Oncol 2011, 13:926-942.
26. Katila O., Lappalainen A. Fluctuations in the total protein content of the cerebrospinal fluid in patients with neurosyphilis. Duodecim 1960, 76:61-68.
27. Khwaja F.W., Duke-Cohan J.S., Brat D.J., Van Meir E.G. Attractin is elevated in the cerebrospinal fluid of patients with malignant astrocytoma and mediates glioma cell migration. Clin Cancer Res 2006, 12:6331-6336.
28. Klein D., Kern R.M., Sokol R.Z. A method for quantification and correction of proteins after transfer to immobilization membranes. Biochem Mol Biol Int 1995, 36:59-66.
29. Kohler K., Seitz H. Validation processes of protein biomarkers in serum-a cross platform comparison. Sensors 2012, 12:12710-12728.
30. Krzystek-Korpacka M., Diakowska D., Bania J., Gamian A. Expression stability of common housekeeping genes is differently affected by bowel inflammation and cancer: implications for finding suitable normalizers for inflammatory bowel disease studies. Inflamm Bowel Dis 2014, 20:1147-1156.
31. LeWitt P. Recent advances in CSF biomarkers for Parkinson's disease. Parkinsonism Relat Disord 2012, 18(Suppl 1):S49-S51.
32. Li X., Miyajima M., Mineki R., Taka H., Murayami K., Akai H. Analysis of potential diagnostic biomarkers in cerebrospinal fluid of idiopathic normal pressure hydrocephalus by proteomics. Acta Neurochir (Wien) 2006, 148:859-864.
33. Light M., Minor K.H., DeWitt P., Jasper K.H., Davis S.J. Multiplex array proteomics detects increased MMP-8 in CSF after spinal cord injury. J Neuroinflammation 2012, 9:122.
34. Liu N.K., Xu X.M. Beta-tubulin is a more suitable internal control than beta-actin in western blot analysis of spinal cord tissues after traumatic injury. J Neurotrauma 2006, 23:1794-1801.
35. Lush B., Crowley M.F., Fletcher E., Buchan J.F. Total and differential protein levels in the blood and cerebrospinal fluid in rheumatoid arthritis. Ann Rheum Dis 1951, 10:153-162.
36. Madeddu R., Farace C., Tolu P., Solinas G., Asara Y., Sotgiu M.A., et al. Cytoskeletal proteins in the cerebrospinal fluid as biomarker of multiple sclerosis. Neurol Sci 2013, 34:181-186.
37. Moritz C.P., Marz S.X., Reiss R., Schulenborg T., Friauf E. Epicocconone staining a powerful loading control for Western blots. Proteomics 2014, 14:162-168.
38. Otter T., King S.M., Witman G.B. A two-step procedure for efficient electrotransfer of both high-molecular-weight (greater than 400,000) and low-molecular-weight (less than 20,000) proteins. Anal Biochem 1987, 162:370-377.
39. Papadopoulos N.M., Hess W.C., O'Doherty D., Mc L.J. A procedure for the determination of cerebrospinal fluid total protein and gamma globulin in neurologic disorders. Clin Chem 1959, 5:569-574.
40. Pepe M.S., Etzioni R., Feng Z., Potter J.D., et al. Phases of biomarker development for early detection of cancer. J Natl Cancer Inst 2001, 93:1054-1061.
41. Perez-Perez R., Lopez J.A., Garcia-Santos E., Camafeita E., Gómez-Serrano M., Ortega-Delgado F.J., et al. Uncovering suitable reference proteins for expression studies in human adipose tissue with relevance to obesity. PLoS One 2012, 7:e30326.
42. Persichetti E., Chiasserini D., Parnetti L., Eusebi P., Paciotti S., De Carlo C., et al. Factors influencing the measurement of lysosomal enzymes activity in human cerebrospinal fluid. PLoS One 2014, 9:e101453.
43. Ranganathan S., Williams E., Ganchev P., Gopalakrishnan V., Lacomis D., Urbinelli L., et al. Proteomic profiling of cerebrospinal fluid identifies biomarkers for amyotrophic lateral sclerosis. J Neurochem 2005, 95:1461-1471.
44. Rivero-Gutierrez B., Anzola A., Martinez-Augustin O., Sanchez de Medina F. Stain-free detection as loading control alternative to Ponceau and housekeeping protein immunodetection in Western blotting. Anal Biochem 2014, 467:1-3.
45. Roberts-Thomson P.J., Esiri M.M., Young A.C., Maclennan I.C. Cerebrospinal fluid immunoglobulin quotients, kappa/lambda ratios, and viral antibody titres in neurological disease. J Clin Pathol 1976, 29:1105-1115.
46. Roche S., Gabelle A., Lehmann S. Clinical proteomics of the cerebrospinal fluid: towards the discovery of new biomarkers. Proteomics Clin Appl 2008, 2:428-436.
47. Romero-Calvo I., Ocon B., Martinez-Moya P., Suarez M.D., Zarzuelo A., Martínez-Augustin O., et al. Reversible ponceau staining as a loading control alternative to actin in western blots. Anal Biochem 2010, 401:318-320.
48. Rosenmann H. CSF biomarkers for amyloid and tau pathology in Alzheimer's disease. J Mol Neurosci 2012, 47:1-14.
49. Schutzer S.E., Liu T., Natelson B.H., Angel T.E., Schepmoes A.A., Purvine S.O., et al. Establishing the proteome of normal human cerebrospinal fluid. PLoS One 2010, 5:e10980.
50. Schwarz E., Bahn S. Cerebrospinal fluid: identification of diagnostic markers for schizophrenia. Expert Rev Mol Diagn 2008, 8:209-216.
51. Sidák Z.K. Rectangular confidence regions for the means of multivariate normal distributions. J Am Stat Assoc 1967, 62:626-633.
52. Sidor M.M., Sakic B., Malinowski P.M., Ballok D.A., Oleschuk C.J., Macri J. Elevated immunoglobulin levels in the cerebrospinal fluid from lupus-prone mice. J Neuroimmunol 2005, 165:104-113.
53. Sikand K., Singh J., Ebron J.S., Shukla G.C. Housekeeping gene selection advisory: glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and beta-actin are targets of miR-644a. PLoS One 2012, 7:e47510.
54. Simonsen A.H., Bahl J.M., Danborg P.B., Lindstrom V., Larsen S.O., Grubb A., et al. Pre-analytical factors influencing the stability of cerebrospinal fluid proteins. J Neurosci Methods 2013, 215:234-240.
55. Sternberg S.R. Biomedial image processing. IEEE Trans Comput 1983, 32:22-34.
56. Suon S., Zhao J., Villarreal S.A., Anumula N., Liu M., Carangia L.M., et al. Systemic treatment with liver X receptor agonists raises apolipoprotein E, cholesterol, and amyloid-beta peptides in the cerebral spinal fluid of rats. Mol Neurodegener 2010, 5:44.
57. Taylor S.C., Berkelman T., Yadav G., Hammond M. A defined methodology for reliable quantification of Western blot data. Mol Biotechnol 2013, 55:217-226.
58. Toombs J., Paterson R.W., Lunn M.P., Nicholas J.M., Fox N.C., Chapman M.D., et al. Identification of an important potential confound in CSF AD studies: aliquot volume. Clin Chem Lab Med 2013, 51:2311-2317.
59. Toombs J., Paterson R.W., Schott J.M., Zetterberg H. Amyloid-beta 42 adsorption following serial tube transfer. Alzheimers Res Ther 2014, 6:5.
60. Tsuji-Akimoto S., Yabe I., Niino M., Kikuchi S., Sasaki H. Cystatin C in cerebrospinal fluid as a biomarker of ALS. Neurosci Lett 2009, 452:52-55.
61. Welinder C., Ekblad L. Coomassie staining as loading control in western blot analysis. J Proteome Res 2011, 10:1416-1419.
62. Wilson M.E., Boumaza I., Lacomis D., Bowser R., Cystatin C. a candidate biomarker for amyotrophic lateral sclerosis. PLoS One 2010, 5:e15133.
63. Wong M., Schlaggar B.L., Buller R.S., Storch G.A., Landt M. Cerebrospinal fluid protein concentration in pediatric patients: defining clinically relevant reference values. Arch Pediatr Adolesc Med 2000, 154:827-831.
64. You J.S., Gelfanova V., Knierman M.D., Witzmann F.A., Wang M., Hale J.E. The impact of blood contamination on the proteome of cerebrospinal fluid. Proteomics 2005, 5:290-296.
65. Zappaterra M.W., Lehtinen M.K. The cerebrospinal fluid: regulator of neurogenesis, behavior, and beyond. Cell Mol Life Sci 2012, 69:2863-2878.
66. Zeng L., Guo J., Xu H.B., Huang R., Shao W., Yang L., et al. Direct Blue 71 staining as a destaining-free alternative loading control method for Western blotting. Electrophoresis 2013, 34:2234-2239.